Yin Y, Gong S, Han M, Wang J, Shi H, Jiang X
Anim Nutr. 2024; 16:158-173.
PMID: 38357569
PMC: 10864217.
DOI: 10.1016/j.aninu.2023.10.005.
Song W, Beigneux A, Winther A, Kristensen K, Gronnemose A, Yang Y
J Clin Invest. 2022; 132(5).
PMID: 35229724
PMC: 8884915.
DOI: 10.1172/JCI157500.
Yang Y, Li F, Guo Q, Wang W, Zhang L, Yin Y
Front Vet Sci. 2022; 8:828165.
PMID: 35198620
PMC: 8859423.
DOI: 10.3389/fvets.2021.828165.
Nagasawa T, Kimura T, Yoshida A, Tsunekawa K, Araki O, Ushiki K
Nutrients. 2021; 13(7).
PMID: 34202167
PMC: 8308303.
DOI: 10.3390/nu13072191.
Ying Q, Chan D, Watts G
Front Physiol. 2021; 12:603910.
PMID: 33643062
PMC: 7902499.
DOI: 10.3389/fphys.2021.603910.
The fatty acids from LPL-mediated processing of triglyceride-rich lipoproteins are taken up rapidly by cardiomyocytes.
Jiang H, He C, Fong L, Young S
J Lipid Res. 2020; 61(6):815.
PMID: 32241805
PMC: 7269765.
DOI: 10.1194/jlr.ILR120000783.
Anabolic androgenic steroids exert a selective remodeling of the plasma lipidome that mirrors the decrease of the de novo lipogenesis in the liver.
Balgoma D, Zelleroth S, Gronbladh A, Hallberg M, Pettersson C, Hedeland M
Metabolomics. 2020; 16(1):12.
PMID: 31925559
PMC: 6954146.
DOI: 10.1007/s11306-019-1632-0.
Targeted sequencing of candidate genes of dyslipidemia in Punjabi Sikhs: Population-specific rare variants in GCKR promote ectopic fat deposition.
Sanghera D, Hopkins R, Malone-Perez M, Bejar C, Tan C, Mussa H
PLoS One. 2019; 14(8):e0211661.
PMID: 31369557
PMC: 6675050.
DOI: 10.1371/journal.pone.0211661.
GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism.
Young S, Fong L, Beigneux A, Allan C, He C, Jiang H
Cell Metab. 2019; 30(1):51-65.
PMID: 31269429
PMC: 6662658.
DOI: 10.1016/j.cmet.2019.05.023.
Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis.
Birrane G, Beigneux A, Dwyer B, Strack-Logue B, Kristensen K, Francone O
Proc Natl Acad Sci U S A. 2018; 116(5):1723-1732.
PMID: 30559189
PMC: 6358717.
DOI: 10.1073/pnas.1817984116.
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
Chan D, Watts G, Somaratne R, Wasserman S, Scott R, Barrett P
Arterioscler Thromb Vasc Biol. 2018; 38(7):1644-1655.
PMID: 29880491
PMC: 6039422.
DOI: 10.1161/ATVBAHA.118.310882.
Novel GPIHBP1-independent pathway for clearance of plasma TGs in mice.
Cushing E, Sylvers K, Chi X, Shetty S, Davies B
J Lipid Res. 2018; 59(7):1230-1243.
PMID: 29739862
PMC: 6027919.
DOI: 10.1194/jlr.M084749.
NanoSIMS Analysis of Intravascular Lipolysis and Lipid Movement across Capillaries and into Cardiomyocytes.
He C, Weston T, Jung R, Heizer P, Larsson M, Hu X
Cell Metab. 2018; 27(5):1055-1066.e3.
PMID: 29719224
PMC: 5945212.
DOI: 10.1016/j.cmet.2018.03.017.
Bisphenol S impairs blood functions and induces cardiovascular risks in rats.
Pal S, Sarkar K, Nath P, Mondal M, Khatun A, Paul G
Toxicol Rep. 2017; 4:560-565.
PMID: 29152460
PMC: 5671619.
DOI: 10.1016/j.toxrep.2017.10.006.
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
Norata G, Tavori H, Pirillo A, Fazio S, Catapano A
Cardiovasc Res. 2016; 112(1):429-42.
PMID: 27496869
PMC: 5031950.
DOI: 10.1093/cvr/cvw194.
Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.
Romero M, Lucas R, Dou H, Sridhar S, Czikora I, Mosieri E
Proc Natl Acad Sci U S A. 2016; 113(7):1895-900.
PMID: 26831066
PMC: 4763773.
DOI: 10.1073/pnas.1525520113.
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
Kones R, Rumana U
Drugs. 2015; 75(11):1201-28.
PMID: 26169307
DOI: 10.1007/s40265-015-0429-3.
Structural stability and functional remodeling of high-density lipoproteins.
Gursky O
FEBS Lett. 2015; 589(19 Pt A):2627-39.
PMID: 25749369
PMC: 4561042.
DOI: 10.1016/j.febslet.2015.02.028.
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag. 2013; 9:617-70.
PMID: 24174878
PMC: 3808150.
DOI: 10.2147/VHRM.S37119.
Genetics of lipid traits and relationship to coronary artery disease.
Keenan T, Rader D
Curr Cardiol Rep. 2013; 15(9):396.
PMID: 23881580
PMC: 3883430.
DOI: 10.1007/s11886-013-0396-9.